{"document_type": "article", "snippet": "A father is battling Memorial Sloan Kettering Cancer Center over the rights to developing a gene therapy that he hopes could cure his son\u2019s blood disease.", "type_of_material": "News", "web_url": "http://www.nytimes.com/2015/10/16/business/lawsuit-accuses-sloan-kettering-of-delaying-gene-therapy-for-rare-blood-disease.html", "subsection_name": null, "blog": [], "section_name": "Business Day", "source": "The New York Times", "pub_date": "2015-10-16T00:00:00Z", "word_count": "1778", "slideshow_credits": null, "news_desk": "Business", "byline": {"original": "By ANDREW POLLACK", "person": [{"role": "reported", "lastname": "POLLACK", "rank": 1, "organization": "", "firstname": "Andrew"}]}, "abstract": "Patrick Girondi, founder of Errant Gene Therapeutics, is suing Memorial Sloan Kettering Cancer Center over rights to developing gene therapy that he hopes could cure his son of inherited blood disease called beta thalassemia, or Cooley's anemia; claims that Sloan Kettering is not moving therapy forward due to ties between Dr Craig B Thompson, center's president, and rival firm Bluebird Bio", "keywords": [{"value": "Girondi, Patrick (1957- )", "rank": "1", "name": "persons", "is_major": "Y"}, {"value": "Memorial Sloan-Kettering Cancer Center", "rank": "2", "name": "organizations", "is_major": "Y"}, {"value": "Blood", "rank": "3", "name": "subject", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "rank": "4", "name": "subject", "is_major": "Y"}, {"value": "Genetic Engineering", "rank": "5", "name": "subject", "is_major": "N"}, {"value": "Sickle Cell Anemia", "rank": "6", "name": "subject", "is_major": "N"}, {"value": "Clinical Trials", "rank": "7", "name": "subject", "is_major": "N"}, {"value": "Anemia", "rank": "8", "name": "subject", "is_major": "N"}, {"value": "Suits and Litigation (Civil)", "rank": "9", "name": "subject", "is_major": "N"}], "print_page": "1", "multimedia": [{"subtype": "wide", "legacy": {"wideheight": "126", "wide": "images/2015/10/16/business/16gene-web1/16gene-web1-thumbWide.jpg", "widewidth": "190"}, "type": "image", "width": 190, "height": 126, "url": "images/2015/10/16/business/16gene-web1/16gene-web1-thumbWide.jpg"}, {"subtype": "xlarge", "legacy": {"xlargeheight": "900", "xlargewidth": "600", "xlarge": "images/2015/10/16/business/16gene-web1/16gene-web1-articleLarge.jpg"}, "type": "image", "width": 600, "height": 900, "url": "images/2015/10/16/business/16gene-web1/16gene-web1-articleLarge.jpg"}, {"subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/10/16/business/16gene-web1/16gene-web1-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "type": "image", "width": 75, "height": 75, "url": "images/2015/10/16/business/16gene-web1/16gene-web1-thumbStandard.jpg"}], "lead_paragraph": "A father is battling Memorial Sloan Kettering Cancer Center over the rights to developing a gene therapy that he hopes could cure his son\u2019s blood disease.", "headline": {"print_headline": "A Father\u2019s Fight for a Gene Therapy", "main": "Streetwise Father Takes On Sloan Kettering to Save His Sick Son"}, "_id": "561fedbe38f0d84dbbafdf91"}